Company Description
Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases.
The company’s lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.
Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.
The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022.
Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2012 |
| IPO Date | May 9, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Dirk Thye |
Contact Details
Address: 611 Gateway Boulevard, Suite 273 South San Francisco, California 94080 United States | |
| Phone | 415-910-5717 |
| Website | quincetx.com |
Stock Details
| Ticker Symbol | QNCX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001145404 |
| CUSIP Number | 22053A107 |
| ISIN Number | US22053A1079 |
| Employer ID | 04-3523569 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Dirk Thye M.D. | Chief Executive Officer, Chief Medical Officer and Director |
| Dr. Charles S. Ryan J.D., Ph.D. | President |
| Brendan Hannah M.B.A. | Chief Business Officer, Chief Operating Officer, Chief Compliance Officer and Principal Financial and Accounting Officer |
| Giovanni Mambrini M.Sc. | Chief Technology Officer |
| Dr. Guenter R. Janhofer M.D., Ph.D. | Chief Scientific Officer |
| Stacy Roughan | Vice President of Corporate Communications and Investor Relations |
| Mary Ellen Sillivos | Vice President of Human Resources |
| Dr. Stewart A. Low Ph.D. | Head of Discovery |
| Thomas Sabia M.B.A. | Chief Commercial Officer |
| Pamela M. Williamson FRAPS, M.B.A., RAC | Head of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2014 | 15-12G | Securities registration termination |
| Feb 12, 2014 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 12, 2014 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 12, 2014 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 12, 2014 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 12, 2014 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 12, 2014 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 12, 2014 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 7, 2014 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 5, 2014 | RW | Filing |